H.C. Wainwright assumed coverage of Monopar Therapeutics (MNPR) with a Buy rating and $70 price target The firm views ALXN1840 as “profoundly misunderstood” and believes the therapy is positioned for a new drug application submission in early 2026. The analyst is constructive that ALXN1840 can become the first major therapeutic advance in Wilson disease in over three decades.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR: